Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study
Background Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy. Aim The aim of this study was to provide useful insight into the antibody generation taking place post-immunization i...
Saved in:
| Published in | Aging clinical and experimental research Vol. 33; no. 12; pp. 3385 - 3389 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.12.2021
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1720-8319 1594-0667 1720-8319 |
| DOI | 10.1007/s40520-021-01997-7 |
Cover
| Abstract | Background
Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy.
Aim
The aim of this study was to provide useful insight into the antibody generation taking place post-immunization in elderly individuals aged over 85.
Methods
In the first phase of our study, antibody levels were monitored in a total of 400 participants, while our final sample consisted of 297 subjects. Humoral immune responses were recorded in 69.75% (95% CI 65.25–74.25) of vaccinees post-first dose and in 98.99% (95% CI 97.85–100) post-second dose.
Results
Overall, a remarkable 40-fold change in IgG levels was observed between the two doses. Subjects displaying low antibody levels after the first dose had significantly higher IgG fold changes than vaccinees whose initial antibody levels were high.
Conclusion
Taken together, our findings highlighted the high fold change (41.18) recorded in the titers of neutralizing antibodies after the second dose suggesting the need for its timely administration to elderly individuals. |
|---|---|
| AbstractList | BackgroundElderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy.AimThe aim of this study was to provide useful insight into the antibody generation taking place post-immunization in elderly individuals aged over 85.MethodsIn the first phase of our study, antibody levels were monitored in a total of 400 participants, while our final sample consisted of 297 subjects. Humoral immune responses were recorded in 69.75% (95% CI 65.25–74.25) of vaccinees post-first dose and in 98.99% (95% CI 97.85–100) post-second dose.ResultsOverall, a remarkable 40-fold change in IgG levels was observed between the two doses. Subjects displaying low antibody levels after the first dose had significantly higher IgG fold changes than vaccinees whose initial antibody levels were high.ConclusionTaken together, our findings highlighted the high fold change (41.18) recorded in the titers of neutralizing antibodies after the second dose suggesting the need for its timely administration to elderly individuals. Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy. The aim of this study was to provide useful insight into the antibody generation taking place post-immunization in elderly individuals aged over 85. In the first phase of our study, antibody levels were monitored in a total of 400 participants, while our final sample consisted of 297 subjects. Humoral immune responses were recorded in 69.75% (95% CI 65.25-74.25) of vaccinees post-first dose and in 98.99% (95% CI 97.85-100) post-second dose. Overall, a remarkable 40-fold change in IgG levels was observed between the two doses. Subjects displaying low antibody levels after the first dose had significantly higher IgG fold changes than vaccinees whose initial antibody levels were high. Taken together, our findings highlighted the high fold change (41.18) recorded in the titers of neutralizing antibodies after the second dose suggesting the need for its timely administration to elderly individuals. Background Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy. Aim The aim of this study was to provide useful insight into the antibody generation taking place post-immunization in elderly individuals aged over 85. Methods In the first phase of our study, antibody levels were monitored in a total of 400 participants, while our final sample consisted of 297 subjects. Humoral immune responses were recorded in 69.75% (95% CI 65.25–74.25) of vaccinees post-first dose and in 98.99% (95% CI 97.85–100) post-second dose. Results Overall, a remarkable 40-fold change in IgG levels was observed between the two doses. Subjects displaying low antibody levels after the first dose had significantly higher IgG fold changes than vaccinees whose initial antibody levels were high. Conclusion Taken together, our findings highlighted the high fold change (41.18) recorded in the titers of neutralizing antibodies after the second dose suggesting the need for its timely administration to elderly individuals. Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy.BACKGROUNDElderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy.The aim of this study was to provide useful insight into the antibody generation taking place post-immunization in elderly individuals aged over 85.AIMThe aim of this study was to provide useful insight into the antibody generation taking place post-immunization in elderly individuals aged over 85.In the first phase of our study, antibody levels were monitored in a total of 400 participants, while our final sample consisted of 297 subjects. Humoral immune responses were recorded in 69.75% (95% CI 65.25-74.25) of vaccinees post-first dose and in 98.99% (95% CI 97.85-100) post-second dose.METHODSIn the first phase of our study, antibody levels were monitored in a total of 400 participants, while our final sample consisted of 297 subjects. Humoral immune responses were recorded in 69.75% (95% CI 65.25-74.25) of vaccinees post-first dose and in 98.99% (95% CI 97.85-100) post-second dose.Overall, a remarkable 40-fold change in IgG levels was observed between the two doses. Subjects displaying low antibody levels after the first dose had significantly higher IgG fold changes than vaccinees whose initial antibody levels were high.RESULTSOverall, a remarkable 40-fold change in IgG levels was observed between the two doses. Subjects displaying low antibody levels after the first dose had significantly higher IgG fold changes than vaccinees whose initial antibody levels were high.Taken together, our findings highlighted the high fold change (41.18) recorded in the titers of neutralizing antibodies after the second dose suggesting the need for its timely administration to elderly individuals.CONCLUSIONTaken together, our findings highlighted the high fold change (41.18) recorded in the titers of neutralizing antibodies after the second dose suggesting the need for its timely administration to elderly individuals. |
| Author | Katsioulis, Christos Kontopoulou, Konstantina Nakas, Christos Theodore Ntotsi, Paschalina Papazisis, Georgios Ainatzoglou, Alexandra Ifantidou, Athina |
| Author_xml | – sequence: 1 givenname: Konstantina surname: Kontopoulou fullname: Kontopoulou, Konstantina organization: Laboratory of Microbiology, “G. Gennimatas” General Hospital – sequence: 2 givenname: Christos Theodore surname: Nakas fullname: Nakas, Christos Theodore organization: Laboratory of Biometry, University of Thessaly, University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern – sequence: 3 givenname: Alexandra surname: Ainatzoglou fullname: Ainatzoglou, Alexandra organization: Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki – sequence: 4 givenname: Athina surname: Ifantidou fullname: Ifantidou, Athina organization: Laboratory of Microbiology, “G. Gennimatas” General Hospital – sequence: 5 givenname: Paschalina surname: Ntotsi fullname: Ntotsi, Paschalina organization: Committee of Hospital Infections, “G. Gennimatas” General Hospital – sequence: 6 givenname: Christos surname: Katsioulis fullname: Katsioulis, Christos organization: Committee of Hospital Infections, “G. Gennimatas” General Hospital – sequence: 7 givenname: Georgios orcidid: 0000-0003-1641-9095 surname: Papazisis fullname: Papazisis, Georgios email: papazisg@auth.gr organization: Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Clinical Trials Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34633648$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctu1DAUhiNURC_wAiyQJTZsAr7FjlkgDaMyjFRaqSqIneUkJ1NXiT3YyUgRL8Oz8GR4ZkopXXTly_n-3-f4P84OnHeQZS8Jfkswlu8ixwXFOaYkx0Qpmcsn2RGR6apkRB3c2x9mxzHeYMxJOjzLDhkXjAleHmU_l30_Or8CZ2s7TMi3aLgG9PH8ighaUdRfns_Q3G9skxOFNqaurQNkHYKugdBNaA1-3QHyGwioLH7_msCEuLUxqx23CAA1vN-5Li5Pv82-L79coDiMzfQ8e9qaLsKL2_Uk-_rp9Gr-OT-7WCzns7O85pIPeWtawaBquFSEM1UVvGmNaJkUhNayErxq24orIEpUvGSpqBoKFMuiqsqacXaSfdj7rseqh6YGNwTT6XWwvQmT9sbq_yvOXuuV3-iywDR9VDJ4c2sQ_I8R4qB7G2voOuPAj1HTosSKMSxoQl8_QG_8GFwaT1OBVUGL9O-JenW_o7tW_uaSALoH6uBjDNDeIQTrbfh6H75O4etd-FomUflAlCI1g_XbqWz3uJTtpTG941YQ_rX9iOoPeQvCbw |
| CitedBy_id | crossref_primary_10_3390_v14051086 crossref_primary_10_3389_fragi_2022_836642 |
| Cites_doi | 10.1016/j.arr.2020.101205 10.1056/NEJMoa2027906 10.2807/1560-7917.ES.2021.26.6.2100096 10.2139/ssrn.3800040 10.1101/2021.04.19.21255714 10.1101/2021.03.16.21253686 10.1101/2021.04.19.21255461 10.1101/2021.01.27.21250612 10.1101/2021.02.03.21251054 10.1093/cid/ciab381 10.1056/NEJMoa2101765 10.1016/S0140-6736(21)00947-8 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 – notice: 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. – notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s40520-021-01997-7 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Eastern Edition MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1720-8319 |
| EndPage | 3389 |
| ExternalDocumentID | PMC8502633 34633648 10_1007_s40520_021_01997_7 |
| Genre | Journal Article |
| GeographicLocations | Greece |
| GeographicLocations_xml | – name: Greece |
| GroupedDBID | -EM 06D 0R~ 203 23M 29~ 2JY 30V 4.4 406 53G 5GY 7X7 8FI 8FJ 8UJ 96X AAAVM AAEWM AAHNG AAIAL AAJKR AAJSJ AAKKN AANXM AANZL AARHV AARTL AASML AATVU AAUYE AAYIU AAYQN AAYTO AAZMS ABAKF ABDZT ABECU ABEEZ ABFTV ABHLI ABIPD ABJNI ABJOX ABKCH ABMQK ABPLI ABQBU ABTEG ABTKH ABTMW ABUWG ABXPI ACACY ACCUX ACGFO ACGFS ACHSB ACKNC ACMLO ACOKC ACREN ACUDM ACULB ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADURQ ADYFF ADYOE ADZKW AEBTG AEFQL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AETCA AEXYK AFBBN AFGXO AFKRA AFLOW AFQWF AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHSBF AIAKS AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKLTO AKMHD ALFXC ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AMXSW AMYLF AMYQR ANMIH ASPBG AUKKA AVWKF AXYYD AZFZN BENPR BGNMA BPHCQ BVXVI C24 C6C CCPQU CSCUP DNIVK DPUIP EBLON EBS EIOEI EJD ESBYG F5P FERAY FFXSO FINBP FNLPD FRRFC FSGXE FYJPI FYUFA GGCAI GGRSB GJIRD GQ7 GRRUI HG6 HMCUK HZ~ I0C IKXTQ IMOTQ ITM IWAJR J-C JZLTJ KOV LLZTM M4Y NQJWS NU0 O9- O93 O9G O9J P2P PQQKQ RLLFE ROL RSV SCLPG SDE SISQX SJN SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 TSG U9L UG4 UKHRP UOJIU UTJUX UZXMN VFIZW W48 Z7U Z82 Z87 ZMTXR ZOVNA AAYXX ABDBE ABFSG ACSTC AEZWR AFHIU AHWEU AIXLP AYFIA CITATION CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c474t-faf63ebd4791439b54dfa6f37612c7b64bffb49e196b483dfa9d2e2075bb8c343 |
| IEDL.DBID | AGYKE |
| ISSN | 1720-8319 1594-0667 |
| IngestDate | Thu Aug 21 18:10:10 EDT 2025 Fri Sep 05 13:59:54 EDT 2025 Mon Jun 30 04:19:06 EDT 2025 Thu Apr 03 07:02:01 EDT 2025 Thu Apr 24 22:51:23 EDT 2025 Tue Jul 01 03:39:56 EDT 2025 Fri Feb 21 02:47:33 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Greece Antibodies Elderly over age 85 SARS-CoV-2 Immunogenicity BNT162b2 mRNA Covid-19 vaccine |
| Language | English |
| License | 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-faf63ebd4791439b54dfa6f37612c7b64bffb49e196b483dfa9d2e2075bb8c343 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-1641-9095 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8502633 |
| PMID | 34633648 |
| PQID | 2609525364 |
| PQPubID | 4402923 |
| PageCount | 5 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8502633 proquest_miscellaneous_2580933062 proquest_journals_2609525364 pubmed_primary_34633648 crossref_primary_10_1007_s40520_021_01997_7 crossref_citationtrail_10_1007_s40520_021_01997_7 springer_journals_10_1007_s40520_021_01997_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-01 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: Germany – name: Heidelberg |
| PublicationTitle | Aging clinical and experimental research |
| PublicationTitleAbbrev | Aging Clin Exp Res |
| PublicationTitleAlternate | Aging Clin Exp Res |
| PublicationYear | 2021 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | Collier, Ferreira, I, Datir R, Kotagiri P, Lim E, Meng B (CR11) 2021 Walsh, Frenck, Falsey, Kitchin, Absalon, Gurtman (CR4) 2020; 383 Haas, Angulo, McLaughlin, Anis, Singer, Khan (CR3) 2021; 397 Mason, Whitston, Hodgson, Watkinson, Lau, Abdulrazeg (CR10) 2021 Chodick, Tene, Patalon, Gazit, Ben Tov, Cohen (CR12) 2021 Kontopoulou, Ainatzoglou, Nakas, Ifantidou, Goudi, Antoniadou (CR6) 2021 Yelin, Katz, Herzel, Berman-Zilberstein, Ben-Tov, Kuint (CR9) 2021 Naaber, Jürjenson, Adamson (CR8) 2021 Chen, Klein, Garibaldi, Li, Wu, Osevala (CR1) 2021; 65 Dagan, Barda, Kepten, Miron, Perchik, Katz (CR2) 2021; 384 Abu Jabal, Ben-Amram, Beiruti, Batheesh, Sussan, Zarka (CR5) 2021; 26 Müller, Andrée, Moskorz, Drexler, Walotka, Grothmann (CR7) 2021 N Dagan (1997_CR2) 2021; 384 I Yelin (1997_CR9) 2021 P Naaber (1997_CR8) 2021 DA Collier (1997_CR11) 2021 K Abu Jabal (1997_CR5) 2021; 26 Y Chen (1997_CR1) 2021; 65 EE Walsh (1997_CR4) 2020; 383 T Mason (1997_CR10) 2021 G Chodick (1997_CR12) 2021 K Kontopoulou (1997_CR6) 2021 EJ Haas (1997_CR3) 2021; 397 L Müller (1997_CR7) 2021 |
| References_xml | – volume: 65 start-page: 101 year: 2021 end-page: 205 ident: CR1 article-title: Aging in COVID-19: vulnerability, immunity and intervention publication-title: Ageing Res Rev doi: 10.1016/j.arr.2020.101205 – volume: 383 start-page: 2439 year: 2020 end-page: 2450 ident: CR4 article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates publication-title: N Engl J Med doi: 10.1056/NEJMoa2027906 – volume: 26 start-page: 2100096 year: 2021 ident: CR5 article-title: Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021 publication-title: Eurosurveillance doi: 10.2807/1560-7917.ES.2021.26.6.2100096 – year: 2021 ident: CR6 article-title: Second dose of the BNT162b2 mRNA vaccine in Greece: the value of timely administration publication-title: SSRN Electron J doi: 10.2139/ssrn.3800040 – year: 2021 ident: CR8 article-title: Antibody response after COVID-19 mRNA vaccination in relation to age, sex, and side effects publication-title: MedRxiv doi: 10.1101/2021.04.19.21255714 – year: 2021 ident: CR9 article-title: Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities publication-title: MedRxiv doi: 10.1101/2021.03.16.21253686 – year: 2021 ident: CR10 article-title: Effects of BNT162b2 mRNA vaccine on Covid-19 infection and hospitalisation among older people: matched case control study for England publication-title: MedRxiv doi: 10.1101/2021.04.19.21255461 – year: 2021 ident: CR12 article-title: The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13–24 days after immunization: real-world evidence publication-title: MedRxiv doi: 10.1101/2021.01.27.21250612 – year: 2021 ident: CR11 article-title: Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2 publication-title: MedRxiv doi: 10.1101/2021.02.03.21251054 – year: 2021 ident: CR7 article-title: Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination publication-title: Clin Infect Dis doi: 10.1093/cid/ciab381 – volume: 384 start-page: 142 year: 2021 end-page: 1423 ident: CR2 article-title: BNT162b2 mRNA Covid-19 vaccine in a Nationwide mass vaccination setting publication-title: N Engl J Med doi: 10.1056/NEJMoa2101765 – volume: 397 start-page: 1819 year: 2021 end-page: 1829 ident: CR3 article-title: Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data publication-title: Lancet doi: 10.1016/S0140-6736(21)00947-8 – volume: 384 start-page: 142 year: 2021 ident: 1997_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101765 – year: 2021 ident: 1997_CR8 publication-title: MedRxiv doi: 10.1101/2021.04.19.21255714 – year: 2021 ident: 1997_CR9 publication-title: MedRxiv doi: 10.1101/2021.03.16.21253686 – year: 2021 ident: 1997_CR10 publication-title: MedRxiv doi: 10.1101/2021.04.19.21255461 – volume: 397 start-page: 1819 year: 2021 ident: 1997_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(21)00947-8 – year: 2021 ident: 1997_CR7 publication-title: Clin Infect Dis doi: 10.1093/cid/ciab381 – year: 2021 ident: 1997_CR12 publication-title: MedRxiv doi: 10.1101/2021.01.27.21250612 – volume: 65 start-page: 101 year: 2021 ident: 1997_CR1 publication-title: Ageing Res Rev doi: 10.1016/j.arr.2020.101205 – volume: 26 start-page: 2100096 year: 2021 ident: 1997_CR5 publication-title: Eurosurveillance doi: 10.2807/1560-7917.ES.2021.26.6.2100096 – year: 2021 ident: 1997_CR11 publication-title: MedRxiv doi: 10.1101/2021.02.03.21251054 – volume: 383 start-page: 2439 year: 2020 ident: 1997_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa2027906 – year: 2021 ident: 1997_CR6 publication-title: SSRN Electron J doi: 10.2139/ssrn.3800040 |
| SSID | ssj0041319 |
| Score | 2.306836 |
| Snippet | Background
Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national... Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority... BackgroundElderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national... Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3385 |
| SubjectTerms | Aged Antibodies BNT162 Vaccine Coronaviruses COVID-19 COVID-19 Vaccines Geriatrics/Gerontology Greece Humans Medicine Medicine & Public Health Older people RNA, Messenger SARS-CoV-2 Short Communication |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXLggoDwCBRkJcQGLjZ8xF7RULS1SF6lq0d4i27HVldqksFuk5dcz482mWip6tp3EmYc_29_MEPKWlwCqR9YwNXKKySAEc0FrJpMyMriUKofRyEcTfXAqv03VtD9wm_e0yrVPzI666QKekX_kmBmNK6Hl58ufDKtG4e1qX0LjLrmXU5eBPpvpsOEC_5wLe8CKLTHS3vRBMzl0TiIBhCFBYZQzkprNhekG2rxJmvzn5jQvSPsPyYMeSdLxSvSPyJ3YPibb4xZ20RdL-o5mbmc-NN8mfw4xDKQDZZkFgN20SxSAH_0yOYGf6Dm9OJ6M6S7G5LHS0t8u4HU7nbU0YhHv8yVdEc0p8j1ppegS7GOOTwFvhN2QvRPip_zQr8d7P8bTw6PvNKeufUJO9_dOdg9YX3WBBWnkgiWXtIi-kcYClrJeySY5ncARlTwYr6VPyUsbwXS9rAQ02oZHDtDD-yoIKZ6SrbZr43NCfRBRC12NrAcUIb1vRLRN6YTX0VkVClKuf3kd-pTkWBnjvB6SKWcx1SCmOoupNgV5P4y5XCXkuLX3zlqSdW-c8_palQryZmgGs8K7EtfG7gr6qCqf9WhekGcrwQ-vE1ILGFwVxGyoxNABU3ZvtrSzs5y6u1Kw5xWiIB_WynP9Wf-fxYvbZ_GS3OeoyJlks0O2Fr-u4iuASgv_OtvDX83jDS8 priority: 102 providerName: ProQuest |
| Title | Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study |
| URI | https://link.springer.com/article/10.1007/s40520-021-01997-7 https://www.ncbi.nlm.nih.gov/pubmed/34633648 https://www.proquest.com/docview/2609525364 https://www.proquest.com/docview/2580933062 https://pubmed.ncbi.nlm.nih.gov/PMC8502633 |
| Volume | 33 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFD5inYR44bJxCYzJSIgXyNTEl8S8ZVN3AbWgakXlKbIdR0xsKaItUuHP8Fv4ZRw7F9QNkPYUKT52fDk-Oba_8xngeRyhU92XScj7iofMUBoqI0TISp4wo8oyVS4aeTgSxxP2ZsqnTVDYvEW7t0eS3lJ3wW7MQTZCBynoew7RZAM2eZTKtAeb2dHHt4PWAqNdjmQTIPP3nOs_oSue5VWA5KVTUv_zObwDk7baNebk895yoffM90uMjtdt11243XijJKvV5x7csNUWbGcVrsQvVuQF8fhQv_G-BTeHzTH8Nvw4cVElM9Q9fLFYkVlJ0I8k-6NTHBMdk4vxKCMHLsQvjCT5pozLRs4qYt2d4OcrUuPWiYOPkpT_-rnC-TZ3xaB1c3IODWTsa1_q0XjwIZueDN8RT4V7HyaHg9OD47C5xSE0LGGLsFSloFYXLJHom0nNWVEqUaJhi2KTaMF0WWomLZoCzVKKibKIbYyujNapoYw-gF41q-wjINpQK6hI-1KjV8K0LqiVRaSoFlZJbgKI2mHNTUNx7m7aOM87cmbf2Tl2du47O08CeNnl-VITfPxXeqfVlryZ7PM8dqR9MaeCBfCsS8Zp6s5eVGVnS5Thqd87EnEAD2vl6j5HmaCYOQ0gWVO7TsBRgK-nVGefPBV4ynENTWkAr1rd-lOtf7fi8fXEn8Ct2KmnB_HsQG_xdWmfoiu20LuwkUyT3Wb-4XN_MHo__g25DixA |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-N7gFeEDA-AgOMBLxARGs7ToKEUDc6WrYWVHVT30LsOKLSlg7agcofxd_InfMxlYm97dkfiX3n88_27-4AnvMOgup2HPpBOw18aYTwU6OUL_MglCbN8yglb-ThSPUP5adpMN2AP7UvDNEqa5voDHU2N3RH_oZTZDQeCCXfn373KWsUva7WKTRKtdi3q194ZFu8G3xA-b7gfK832e37VVYB38hQLv08zZWwOpNhjFgh1oHM8lTluNA63IRaSZ3nWsYWVVPLSGBhnHHLcWvVOjJCCuz3GmxK8mhtweZOb_RlXNt-3BFcKhHECJJ8-8PKTcc560minPhEiWi7GKjh-lZ4Ad9epGn-81brtsC9W3Czwq6sWyrbbdiwxR3Y6hZ4bj9ZsZfMsUndNf0W_B6Q48kc1XNmEOizec4QarKd0QTFpjk7GY-6bJe8AP1OzH6mhh742axgltKGH69YSW1nxDBlUcBWOPUL6gXtH1UjvpCxb12nH8e9o-50MPzMXLDcu3B4JRK5B61iXtgHwLQRVgkVtWONuEVqnQkbZ51UaGXTODAedOopT0wVBJ1ycRwnTfhmJ6YExZQ4MSWhB6-aNqdlCJBLa2_Xkkwqc7BIzpXXg2dNMS5kep1JCzs_wzpB5G6XFPfgfin45nNCKoGNIw_CNZVoKlCQ8PWSYvbNBQuPAjxlC-HB61p5zn_r_6N4ePkonsL1_mR4kBwMRvuP4AYnpXYUn21oLX-c2ccI1Jb6SbU6GHy96gX5FzX7TI4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3bbtQwEB1BK1W8IGi5BAoYCfECUTfxJTFvoXTpLuyCSov2LbIdW1RqsxVNkVb8DN_ClzF2soGlgMRrPM5tZpzj-MwxwJM0QVA9kFnMB4rHzFAaKyNEzBzPmFHO5cpXI0-mYv-IjWd89ksVf2C7L5ck25oGr9JUNztnldvpC9-Yp2_Enl4wCHqi2VVYzxGL4_RrvSjGH8bL0RjH6ER2xTJ_7rn6QbqEMi-TJX9bMQ0fouENuN4hSFK0Lr8JV2y9CVtFjbPn0wV5SgKnM_ws34SNSbd0vgVfR74SZI7xggeaBZk7gtiPvJwe4nvUKTk9mBZk15flxYkkX5Tx3chxTazfx_tkQVquOfGUT5Lz798WmCPn_jQ4Ink7z-Ax9kU46-uDvY_FbDR5R4J87S04Gu4d7u7H3c4LsWEZa2KnnKBWVyyTiKek5qxySjgcjJLUZFow7Zxm0mL6apZTbJRValOEH1rnhjJ6G9bqeW3vAtGGWkFFPpAakQTTuqJWVomiWlgluYkgWb7-0nSy5H53jJOyF1QOLivRZWVwWZlF8Kzvc9aKcvzTenvp1bJL0PMy9UJ7KaeCRfC4b8bU8uslqrbzC7ThefjfI9II7rRB0F-OMkGxcx5BthIevYGX7V5tqY8_BfnunOO8l9IIni8D6edt_f0p7v2f-SPYeP9qWL4dTd_ch2upj_fAwdmGtebzhX2ASKrRD7tk-QECahU2 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunogenicity+of+the+BNT162b2+mRNA+Covid-19+vaccine+in+elderly+people+over+85%C2%A0years+of+age+in+Greece%3A+the+GREVAXIMO+study&rft.jtitle=Aging+clinical+and+experimental+research&rft.au=Kontopoulou%2C+Konstantina&rft.au=Nakas%2C+Christos+Theodore&rft.au=Ainatzoglou%2C+Alexandra&rft.au=Ifantidou%2C+Athina&rft.date=2021-12-01&rft.pub=Springer+International+Publishing&rft.eissn=1720-8319&rft.volume=33&rft.issue=12&rft.spage=3385&rft.epage=3389&rft_id=info:doi/10.1007%2Fs40520-021-01997-7&rft.externalDocID=10_1007_s40520_021_01997_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1720-8319&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1720-8319&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1720-8319&client=summon |